When Insider Selling Is a Good Thing: 2 Stocks to Watch

Why It Matters

The selling reflects profit‑taking rather than deteriorating prospects, highlighting that both stocks could deliver attractive returns as they rebound, which is critical for dividend investors and biotech growth seekers alike.

Key Takeaways

• Waste Management insiders sold ~$25M, still strong dividend.
• Institutional owners hold ~80% of WM, accumulating.
• Ionis insiders and institutions selling, but Olezarsen drives upside.
• Analysts forecast ~25% near‑term gain for Ionis.
• Both stocks pulled back, creating potential entry points.

Pulse Analysis

Insider selling often triggers alarm, yet seasoned investors recognize it can signal confidence when executives monetize gains without undermining the company’s trajectory. Waste Management’s leadership off‑loaded roughly $25 million after the stock hit an all‑time high in early 2026, but the move represents less than 0.2% of outstanding shares. The firm’s core business—reliable waste collection and disposal—continues to generate robust cash flow, enabling a 1.65% dividend yield and a sustainable payout ratio near 56%. Institutional investors now own about 80% of WM, a level that typically stabilizes volatility and reinforces long‑term price appreciation, especially as the company eyes inclusion in the Dividend Aristocrats Index.

Ionis Pharmaceuticals presents a contrasting narrative. While insiders and institutions have been shedding shares, the catalyst remains the upcoming commercial launch of Olezarsen, an RNA‑based therapy projected to peak at roughly $2 billion in sales. Analysts, despite noting the heavy sell‑off, assign a Moderate Buy rating and anticipate roughly 25% upside by year‑end, underpinned by a 20% annual growth outlook extending into the next decade. The company’s pipeline of RNA therapeutics offers multiple near‑term revenue streams, and a projected 7× earnings multiple for 2035 suggests substantial upside if pipeline milestones are met.

For investors, the synchronized pullbacks in WM and IONS create strategic entry points. WM’s dividend profile appeals to income‑focused portfolios, while Ionis offers high‑growth potential for risk‑tolerant capital. However, participants should weigh the typical volatility of biotech earnings against the steadier cash‑flow dynamics of a utility‑like waste business. Monitoring insider activity, institutional trends, and upcoming catalyst dates—such as Olezarsen’s market launch—will be essential to time re‑entries and capture the upside embedded in these fundamentally sound, albeit temporarily discounted, equities.